Fate Therapeutics (FATE) Cash from Investing Activities (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Cash from Investing Activities data on file, last reported at $23.6 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 44.73% year-over-year to $23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.1 million (up 145.04% YoY) and the FY2025 annual result came in at $111.2 million, up 809.85% from the prior year.
• Cash from Investing Activities eased to $23.6 million in Q1 2026, from $27.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $80.4 million in Q3 2022 to a low of -$53.4 million in Q2 2024.
• A 5-year average of $25.1 million and a median of $24.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 3036.37% — and 2024, when it sank 260.92%.
• Tracing FATE's Cash from Investing Activities over 5 years: stood at $53.1 million in 2022, then fell by 14.61% to $45.4 million in 2023, then plunged by 49.69% to $22.8 million in 2024, then increased by 21.1% to $27.6 million in 2025, then retreated by 14.63% to $23.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $23.6 million (Q1 2026), $27.6 million (Q4 2025), and $21.3 million (Q3 2025), per Business Quant data.